RT Journal Article
SR Electronic
T1 Depletion-of-susceptibles bias in influenza vaccine waning studies: how to ensure robust results
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19003616
DO 10.1101/19003616
A1 M. Lipsitch
A1 E. Goldstein
A1 G.T. Ray
A1 B. Fireman
YR 2019
UL http://medrxiv.org/content/early/2019/08/12/19003616.abstract
AB Vaccine effectiveness (VE) studies are subject to biases due to depletion of at-risk persons or of highly susceptible persons at different rates from different groups (depletion-of-susceptibles bias), a problem that can also lead to biased estimates of waning effectiveness, including spurious inference of waning when none exists. An alternative study design to identify waning is to study only vaccinated persons, and compare for each day the incidence in persons with earlier or later dates of vaccination. Prior studies suggested under what conditions this alternative would yield correct estimates of waning. Here we define the depletion-of-susceptibles process formally and show mathematically that for influenza vaccine waning studies, a randomized trial or corresponding observational study that compares incidence at a specific calendar time among individuals vaccinated at different times before the influenza season begins will not be vulnerable depletion-of-susceptibles bias in its inference of waning under the null hypothesis that none exists, and will – if waning does actually occur – underestimate the extent of waning. Such a design is thus robust in the sense that a finding of waning in that inference framework reflects actual waning of vaccine-induced immunity. We recommend such a design for future studies of waning, whether observational or randomized.Competing Interest StatementG. Thomas Ray reports research support from Pfizer. Marc Lipsitch reports support from Merck, Pfizer, Antigen Discovery, and Affinivax. The remaining authors have no potential conflicts of interest to disclose.Funding StatementSupport for this work came from: the National Institute of Allergy and Infectious Diseases, National Institute of Health, USA grant #1R01AI107721-01; cooperative agreement U54GM088558 from the National Institute Of General Medical Sciences, National Institutes of Health USA; UK National Institute for Health Research (NIHR)grant PR-OD-1017-20006 (Epidemiology for Vaccinology stream) using UK aid from the UK government; and The Permanente Medical Group. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences, the National Institutes of Health, the NIHR or the UK Department of Health and Social Care.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.Not ApplicableAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not Applicablenot applicable